Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Belzutifan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exelixis And Merck Sign Clinical Development Collaboration
    Exelixis And Merck Sign Clinical Development Collaboration

    14 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241011501595/en

    BUSINESSWIRE
    14 Oct 2024
    Share Share
    HiberCell: First Patient Dosed In Merck Combo Trial For ccRCC
    HiberCell: First Patient Dosed In Merck Combo Trial For ccRCC

    01 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/01/2873708/0/en/HiberCell-Announces-First-Patient-Dosed-in-Clinical-Collaboration-with-Merck-Evaluating-HC-7366-in-Combination-with-WELIREG-belzutifan-in-patients-with-advanced-ccRCC.html

    GLOBENEWSWIRE
    01 May 2024
    Share Share
    US FDA approves Merck's drug for kidney cancer
    US FDA approves Merck's drug for kidney cancer

    14 Dec 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-mercks-drug-kidney-cancer-2023-12-14/

    REUTERS
    14 Dec 2023
    Share Share
    Merck’s WELIREG Improved Objective Response Rates Versus Everolimus in RCC
    Merck’s WELIREG Improved Objective Response Rates Versus Everolimus in RCC

    21 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231021045639/en

    BUSINESSWIRE
    21 Oct 2023
    Share Share
    At ESMO, Merck touts Welireg's potential in kidney cancer
    At ESMO, Merck touts Welireg's potential in kidney cancer

    21 Oct 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/esmo-merck-encouraged-welireg-results-kidney-cancer

    Kevin Dunleavy FIERCE PHARMA
    21 Oct 2023
    Share Share
    FDA Accepts for Priority Review Merck’s Supplemental NDA for WELIREG
    FDA Accepts for Priority Review Merck’s Supplemental NDA for WELIREG

    19 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230919584956/en

    BUSINESSWIRE
    19 Sep 2023
    Share Share